Editing
Kidney Cancer: Diagnosis and Evaluation
(section)
Jump to navigation
Jump to search
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==== MRI ==== * '''Alternate standard to CT''' ** '''Similar sensitivity and specificity to CT''' ***Sensitivity: 88% (interquartile range [IQR] 81%-94%) CT vs. 87.5% (IQR 75.25%-100%) MRI ***Specificity: 75% (IQR 51%-90%) CT vs. 89% (IQR 75%-96%) MRI ***[https://pubmed.ncbi.nlm.nih.gov/30528378/ Vogel, Christina, et al.] "Imaging in suspected renal-cell carcinoma: systematic review." ''Clinical genitourinary cancer'' 17.2 (2019): e345-e355. **Considered comparable to CT in characterizing indeterminate renal masses by the American College of Radiology[https://pubmed.ncbi.nlm.nih.gov/33153554/] **CT may be better for smaller lesions **'''Most useful in patients in whom contrast is contraindicated because of severe allergy or severe CKD''' ** '''Gadolinium contrast can be given to patients with GFR < 30 mL/min/1.73m2[https://pubmed.ncbi.nlm.nih.gov/33170103/]''' ** '''Nephrogenic systemic fibrosis (NSF)''' *** Fibrosing dermopathy associated with soft tissue deposition and accumulation of gadolinium *** '''Potentially serious complication of gadolinium contrast''' *** '''Very rare''' **** '''More common with group I gadolinium based contrast agents''' ***** Incidence <0.07% in patients with CKD 4 and 5 with group II agents ***** Group II gadolinium based contrast agents are considered safe for any level of eGFR ****** '''Renal function does not need be screened prior to receiving group II gadolinium based contrast agents''' *** '''Prevention in patients with ESRD: perform hemodialysis after the MRI scan.''' * '''Image Sequences''' **Lesions in upper pole and lower pole may be skipped when scrolling through axial slices, always look at coronal images **T2WI ***Most useful for anatomic assessment of renal masses ***Usually two T2 sequences, one with fat suppression and one without ***Renal vessels will be dark **Diffusion weighted imaging ***Sequences with higher b-value more likely useful *'''Enhancement > 20% is suspicious for RCC''' * '''For a fat-containing tumor, a T2-weighted image with fat suppression is most likely to identify macroscopic fat and confirm the diagnosis of an angiomyolipoma (AML).''' * '''Best study for evaluation of invasion into adjacent structures''' ** '''Large tumours may indent and compress adjacent liver parenchyma but seldom actually grow by direct extension into the liver; obliteration of the fat plane between the tumour and adjacent organs (e.g. the liver) on CT can be a misleading finding and should prompt further imaging with MRI'''. In reality, surgical exploration is often required to make an absolute differentiation.
Summary:
Please note that all contributions to UrologySchool.com may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
UrologySchool.com:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Page
Discussion
English
Views
Read
Edit
Edit source
View history
More
Search
Navigation
Main page
Clinical Tools
Guidelines
Chapters
Landmark Studies
Videos
Contribute
For Patients & Families
MediaWiki
Recent changes
Random page
Help about MediaWiki
Tools
What links here
Related changes
Special pages
Page information